Ying Peng, Zhonggen Li, Jianchao Zhang, Yunshu Dong, Chenglin Zhang, Yiming Dong, Yafei Zhai, Honglin Zheng, Mengduan Liu, Jing Zhao, Wenting Du, Yangyang Liu, Liping Sun, Xiaowei Li, Hailong Tao, Deyong Long, Xiaoyan Zhao, Xin Du, Changsheng Ma, Yaohe Wang, Jianzeng Dong
BACKGROUND: The only clinically approved drug that reduces doxorubicin cardiotoxicity is dexrazoxane, but its application is limited due to the risk of secondary malignancies. So, exploring alternative effective molecules to attenuate its cardiotoxicity is crucial. Colchicine is a safe and well-tolerated drug that helps reduce the production of reactive oxygen species. High doses of colchicine have been reported to block the fusion of autophagosomes and lysosomes in cancer cells. However, the impact of colchicine on the autophagy activity within cardiomyocytes remains inadequately elucidated...
May 3, 2024: Journal of the American Heart Association